FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Market Closed - Deutsche Boerse AG 20:49:15 07/06/2024 BST | ||
| 0.039 EUR | +5.41% |
|
| Current month | -27.78% | ||
| 1 month | -35.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 0.039 | +5.41% |
| 06/06/24 | 0.037 | -2.63% |
| 05/06/24 | 0.038 | -9.52% |
| 04/06/24 | 0.042 | -8.70% |
| 03/06/24 | 0.046 | -14.81% |
Delayed Quote Deutsche Boerse AG
Last update June 07, 2024 at 08:49 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SQ4MD3 |
| ISIN | DE000SQ4MD34 |
| Date issued | 21/11/2022 |
| Strike | 10,838 p |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.84 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14 € |
|---|---|
| Lowest since issue | 0.036 € |
| Spread | 0.01 € |
| Spread % | 20.41% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159.8
USD
Average target price
173.1
USD
Spread / Average Target
+8.38%
- Stock Market
- Certificates
- Certificat